Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | EP300 | Q09472 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21296297 | 1.00 | MEN1 (0.64) | MEN1KMT2AMAPK1POLBCASP3 | |
| SCHEMBL18857854 | 0.85 | MEN1 (0.68) | MEN1KMT2AMAPK1POLBCASP3 | |
| SCHEMBL13727246 | 0.85 | MEN1 (0.68) | MEN1KMT2AMAPK1POLBCASP3 | |
| SCHEMBL13727245 | 0.85 | MEN1 (0.68) | MEN1KMT2AMAPK1POLBCASP3 | |
| SCHEMBL10492190 | 0.80 | PTPN12 (0.79) | MEN1KMT2AMAPK1POLBCASP3 | |
| SCHEMBL14652602 | 0.80 | PTPN12 (0.79) | MEN1KMT2AMAPK1POLBCASP3 | |
| SCHEMBL10492188 | 0.80 | PTPN12 (0.79) | MEN1KMT2AMAPK1POLBCASP3 | |
| SCHEMBL12008493 | 0.78 | CISD1 (0.81) | MEN1KMT2AMAPK1POLBCASP3 | |
| SCHEMBL15709015 | 0.78 | CISD1 (0.81) | MEN1KMT2AMAPK1POLBCASP3 | |
| SCHEMBL12010971 | 0.78 | MEN1 (1.00) | MEN1KMT2AMAPK1POLBCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233535-A1 | METHOD FOR THE DETERMINATION OF CLEAVAGE SITES IN GENOMIC DNA CAUSED BY EXPOSURE TO A SITE DIRECTED NUCLEASE | ETH Zürich (CH) | 2025-11-13 | — | — | WO | claimed |
| US-20230332256-A1 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | UNIV JOHNS HOPKINS (US) | 2023-10-19 | — | — | US | claimed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | claimed |
| US-20210079402-A1 | INHIBITION OF ZSCAN4 FOR INHIBITION OF TUMOR GROWTH | UNIVERSITY OF MARYLAND, BALTIMORE | 2021-03-18 | — | — | US | claimed |
| WO-2019164965-A1 | INHIBITION OF ZSCAN4 FOR INHIBITION OF TUMOR GROWTH | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2019-08-29 | — | — | WO | claimed |
| CN-121102210-A | Application of PFM01 in preparation of medicine for resisting gram-positive bacterial infection | 深圳市南山区人民医院 | 2025-12-12 | — | — | CN | disclosed |
| CN-121102210-A | Application of PFM01 in preparation of medicine for resisting gram-positive bacterial infection | 深圳市南山区人民医院 | 2025-12-12 | — | — | CN | disclosed |
| WO-2025233535-A1 | METHOD FOR THE DETERMINATION OF CLEAVAGE SITES IN GENOMIC DNA CAUSED BY EXPOSURE TO A SITE DIRECTED NUCLEASE | ETH Zürich (CH) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025038164-A1 | NICK RESECTION IN CANCER | UNIVERSITY OF MASSACHUSETTS (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4504954-A1 | INCREASING DEVELOPMENTAL POTENTIAL OF HUMAN PREIMPLANTATION EMBRYOS BY REDUCING GENETIC INSTABILITY, ANEUPLOIDIES AND CHROMOSOMAL MOSAICISM | The Trustees Of Columbia University In The City Of New York (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250034520-A1 | INCREASING DEVELOPMENTAL POTENTIAL OF HUMAN PREIMPLANTATION EMBRYOS BY REDUCING GENETIC INSTABILITY, ANEUPLOIDIES AND CHROMOSOMAL MOSAICISM | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-01-30 | — | — | US | disclosed |
| CN-113645736-B | Light-emitting driver for driving light-emitting component at high speed | 茂达电子股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023196677-A1 | INCREASING DEVELOPMENTAL POTENTIAL OF HUMAN PREIMPLANTATION EMBRYOS BY REDUCING GENETIC INSTABILITY, ANEUPLOIDIES AND CHROMOSOMAL MOSAICISM | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-4213948-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | Board of Regents, The University of Texas System (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113995758-B | Application of carbazole-pyrimidine derivative in preparation of antitumor drugs | 中山大学 | 2023-06-02 | — | — | CN | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2022-09-27 | — | — | US | disclosed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022060477-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | MEN1 1727/4885KMT2A 805/4885MAPK1 3578/4885 |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | DNASE1, RNASEH1, FEN1 | MEN1 1573/4885KMT2A 1049/4885MAPK1 3772/4885 |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | DNASE1, RNASEH1, FEN1 | MEN1 1573/4885KMT2A 1049/4885MAPK1 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.